Here's a recent video podcast I just did on the publication just out in Lancet Oncology, describing a randomized phase II study led by my friend Pasi Janne, from Dana Farber Cancer Institute in Boston.
We've touched on this study before, but it's promising enough for the field of lung cancer that it should be covered as the publication comes out, especially since KRAS mutations are actually the most common molecular defect we see in NSCLC, and yet we haven't had an actual treatment to offer such patients in the past. Let's hope this work leads that to change soon.
Hi Oaktowngrrl, Welcome to Grace. I'm so sorry you're going through this.
Finding a reputable dedicated thoracic surgeon for lung surgery might be difficult, as it is a complex and...
Hello Hello, Just want to let you know I see your post and will respond more appropriately in the morning.
I'm sure you're…